Audiologic Monitoring of Multi-drug Resistant Tuberculosis Patients on Aminoglycoside Treatment with Long Term Follow-up

Overview

Journal BMC Ear Nose Throat Disord

Publisher Biomed Central

Specialty Otorhinolaryngology

Date 2007 Nov 14

PMID 17997841

Citations 46

Authors

Prahlad Duggal

Malay Sarkar

Affiliations

Soon will be listed here.

Abstract

Background: Multi-drug resistant tuberculosis has emerged as a significant problem with the resurfacing of tuberculosis and thus the need to use the second line drugs with the resultant increased incidence of adverse effects. We discuss the effect of second line aminoglycoside anti-tubercular drugs on the hearing status of MDR-TB patients.

Methods: Sixty four patients were put on second line aminoglycoside anti-TB drugs. These were divided into three groups: group I, 34 patients using amikacin, group II, 26 patients using kanamycin and group III, 4 patients using capreomycin.

Results: Of these, 18.75% of the patients developed sensorineural hearing loss involving higher frequencies while 6.25% had involvement of speech frequencies also. All patients were seen again approximately one year after aminoglycoside discontinuation and all hearing losses were permanent with no threshold improvement.

Conclusion: Aminoglycosides used in MDR-TB patients may result in irreversible hearing loss involving higher frequencies and can become a hearing handicap as speech frequencies are also involved in some of the patients thus underlining the need for regular audiologic evaluation in patients of MDR-TB during the treatment.

Citing Articles

Predictive model for aminoglycoside induced ototoxicity.

Adeyemo A, Adeolu J, Akinyemi J, Omotade O, Oluwatosin O Front Neurol. 2024; 15:1461823.

PMID: 39555479 PMC: 11563990. DOI: 10.3389/fneur.2024.1461823.

A Variable-Stimulus Distortion Product Otoacoustic Emission Screening Method to Match Cochlear Place-Specific Properties.

Stiepan S, Dhar S Ear Hear. 2024; 46(2):421-432.

PMID: 39407360 PMC: 11832347. DOI: 10.1097/AUD.0000000000001594.

Re-telling the story of aminoglycoside ototoxicity: tales from sub-Saharan Africa.

Adeyemo A, Adedokun B, Adeolu J, Akinyemi J, Omotade O, Oluwatosin O Front Neurol. 2024; 15:1412645.

PMID: 39006231 PMC: 11239550. DOI: 10.3389/fneur.2024.1412645.

Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis.

Maranchick N, Peloquin C J Clin Tuberc Other Mycobact Dis. 2024; 36:100444.

PMID: 38708036 PMC: 11067344. DOI: 10.1016/j.jctube.2024.100444.

Combined Retrospective-Prospective Cohort Study to Know the Risk of Sensorineural Hearing Loss in Patients of Drug Resistant TB Receiving Anti Tuberculous Treatment (ATT) at Tertiary Care Centre in South Gujarat.

Bhavsar K, Chaudhari A, Chauhan J, Patel R, Contractor J, Shamaliya K Indian J Otolaryngol Head Neck Surg. 2023; 75(4):3185-3190.

PMID: 37974733 PMC: 10645687. DOI: 10.1007/s12070-023-03702-8.

References

Barza M, Ioannidis J, Cappelleri J, Lau J . Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996; 312(7027):338-45. PMC: 2350289. DOI: 10.1136/bmj.312.7027.338. View

Ormerod L, Horsfield N . Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis. 1996; 77(1):37-42. DOI: 10.1016/s0962-8479(96)90073-8. View

Jacob L, Aguiar F, Tomiasi A, Tschoeke S, Bitencourt R . Auditory monitoring in ototoxicity. Braz J Otorhinolaryngol. 2007; 72(6):836-44. DOI: 10.1016/s1808-8694(15)31053-3. View

Furin J, Mitnick C, Shin S, Bayona J, Becerra M, Singler J . Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001; 5(7):648-55. View

Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov A, Tupasi T . Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004; 8(11):1382-4. View

De Broe M, Verbist L, Verpooten G . Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother. 1991; 27 Suppl C:41-7. DOI: 10.1093/jac/27.suppl_c.41. View

Selimoglu E . Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007; 13(1):119-26. DOI: 10.2174/138161207779313731. View

Ormerod L . Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull. 2005; 73-74:17-24. DOI: 10.1093/bmb/ldh047. View

Chan E, Iseman M . Current medical treatment for tuberculosis. BMJ. 2002; 325(7375):1282-6. PMC: 1124748. DOI: 10.1136/bmj.325.7375.1282. View

10.

Galloe A, Graudal N, Christensen H, Kampmann J . Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol. 1995; 48(1):39-43. DOI: 10.1007/BF00202170. View

11.

Ali M, Goetz M . A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997; 24(5):796-809. DOI: 10.1093/clinids/24.5.796. View

12.

Fausti S, RAPPAPORT B, Schechter M, Frey R, Ward T, BRUMMETT R . Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: selected case studies. Am J Otolaryngol. 1984; 5(3):177-82. DOI: 10.1016/s0196-0709(84)80009-5. View

13.

Munckhof W, Grayson M, Turnidge J . A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996; 37(4):645-63. DOI: 10.1093/jac/37.4.645. View

14.

Volmink J, Garner P . WITHDRAWN: Interventions for promoting adherence to tuberculosis management. Cochrane Database Syst Rev. 2007; (4):CD000010. DOI: 10.1002/14651858.CD000010. View

15.

Espinal M . The global situation of MDR-TB. Tuberculosis (Edinb). 2003; 83(1-3):44-51. DOI: 10.1016/s1472-9792(02)00058-6. View

16.

Mattie H, Craig W, Pechere J . Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989; 24(3):281-93. DOI: 10.1093/jac/24.3.281. View

17.

Peloquin C . Pharmacology of the antimycobacterial drugs. Med Clin North Am. 1993; 77(6):1253-62. DOI: 10.1016/s0025-7125(16)30191-2. View

18.

Hatala R, Dinh T, Cook D . Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996; 124(8):717-25. DOI: 10.7326/0003-4819-124-8-199604150-00003. View

19.

Lerner S, Schmitt B, Seligsohn R, Matz G . Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med. 1986; 80(6B):98-104. DOI: 10.1016/0002-9343(86)90486-9. View

20.

BRUMMETT R, Fox K . Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother. 1989; 33(6):797-800. PMC: 284232. DOI: 10.1128/AAC.33.6.797. View